Tags : rivaroxaban

Bayer Reports Submission of MAA to EMA for Rivaroxaban to

Shots: Bayer has submitted MAA to EMA based on P-III EINSTEIN-Jr. study evaluating Rivaroxaban vs SOC in 500 children in a ratio (2:1) aged from birth to 17yrs. with documented acute VTE who had started heparin therapy The P-III EINSTEIN-Jr. study results: patients with recurrent VTE (1.2% vs 3.0%), the occurrence of bleeding [10 (all […]Read More